CSE

MINDCURE Signs Exclusive Digital Clinical Data Licensing Agreement with ATMA Journey Centers

Thursday, September 23, 2021 - 8:30am

"We are thrilled to expand our collaboration with the team at ATMA.

Key Points: 
  • "We are thrilled to expand our collaboration with the team at ATMA.
  • This is at the core of what we have built iSTRYM to do," said Ty Tashiro, MINDCURE Senior Translational & Psychometric Architect.
  • "We look forward to helping MINDCURE develop iSTRYM into the leading digital therapeutics platform for therapists conducting psychedelic-assisted psychotherapy," saidDavid Harder, Co-CEO and Co-Founder of ATMA.
  • "Real data from patients will further strengthen and improve the protocols we use and the effectiveness of treatments we deliver at our Journey Centers."

BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteins

Thursday, September 23, 2021 - 8:00am

VANCOUVER, BC, Sept. 23, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has initiated what could be a scientifically groundbreaking study on the reduced ACE2 binding capabilities of the hapten-modified spike protein that is the foundation of BVX-0320, the Company's SARS-CoV-2 vaccine.

Key Points: 
  • Many SARS-CoV-2-infected patients develop pneumonia that may lead to acute respiratory distress, with some patients developing cardiac symptoms and cardiovascular injury.
  • These toxicities may be caused by unwanted binding of the vaccine spike protein to ACE2 receptors in the heart or platelet factor 4.
  • David Berd, MD, Chief Medical Officer of Biovaxys, explained that "Biovaxys will compare the binding of haptenized spike protein with the non-haptenized.
  • BioVaxys is currently finalizing arrangements with a major US academic research institution who will be collaborating with the Company on the study.

BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteins

Thursday, September 23, 2021 - 8:00am

VANCOUVER, BC, Sept. 23, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has initiated what could be a scientifically groundbreaking study on the reduced ACE2 binding capabilities of the hapten-modified spike protein that is the foundation of BVX-0320, the Company's SARS-CoV-2 vaccine.

Key Points: 
  • Many SARS-CoV-2-infected patients develop pneumonia that may lead to acute respiratory distress, with some patients developing cardiac symptoms and cardiovascular injury.
  • These toxicities may be caused by unwanted binding of the vaccine spike protein to ACE2 receptors in the heart or platelet factor 4.
  • David Berd, MD, Chief Medical Officer of Biovaxys, explained that "Biovaxys will compare the binding of haptenized spike protein with the non-haptenized.
  • BioVaxys is currently finalizing arrangements with a major US academic research institution who will be collaborating with the Company on the study.

FSD Pharma Announces Engagement with Capital Markets Communications Providers and Market Maker

Wednesday, September 22, 2021 - 11:30pm

Management has made this decision following a thorough review of capital on hand and allocated these resources to investor relations.

Key Points: 
  • Management has made this decision following a thorough review of capital on hand and allocated these resources to investor relations.
  • North Equities' engagement is for a term of seven months (contract signed July 23, 2021).
  • The FSD Shares will be subject to the statutory hold period of four months and one day.
  • KCSA, a leading New York City-based communications firm, has been engaged month to month to develop strategic communications.

InvestorBrandNetwork Announces M.A.D. Casters Interview with TAAT™ Global Alternatives Inc. CEO Setti Coscarella

Wednesday, September 22, 2021 - 10:57pm

During the interview, Coscarella provided insight into his professional background before discussing TAATs unique approach to giving tobacco smokers the choice to leave nicotine behind while keeping the experiences they love.

Key Points: 
  • During the interview, Coscarella provided insight into his professional background before discussing TAATs unique approach to giving tobacco smokers the choice to leave nicotine behind while keeping the experiences they love.
  • From there, I went on to private equity and spent quite a bit of time working on green energy products, Coscarella said.
  • The company has developed TAAT, which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in Original, Smooth, and Menthol varieties.
  • These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Tower One Construction Update For the Month of August 2021

Wednesday, September 22, 2021 - 7:45pm

Certain statements in this release are forward-looking statements, which include regulatory approvals and other matters.

Key Points: 
  • Certain statements in this release are forward-looking statements, which include regulatory approvals and other matters.
  • Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future.
  • Forward-looking statements in this news release include statements regarding the Companys expectation of obtaining the acceptance of new towers by the Companys customers.
  • The Company assumes no obligation to update any forward-looking statements or forward-looking information referenced herein, whether as a result of new information events or otherwise, except as required by applicable securities laws.

PUDO Inc signs specialized vape product delivery solution agreements with West Coast Vape Supply Inc, and ELiquid Depot

Wednesday, September 22, 2021 - 6:52pm

With its carrier-agnostic parcel pick-up and drop-off counter locations throughout North America, PUDO is the perfect solution for AIV.

Key Points: 
  • With its carrier-agnostic parcel pick-up and drop-off counter locations throughout North America, PUDO is the perfect solution for AIV.
  • Mike Ibrahim, CEO of West Coast Vape Supply says, "We are excited to explore new Delivery opportunities with PUDO and continue to bring harm reduction technologies to our customers.
  • This new Agreement will help solve shipping challenges and we hope new customers who would like to find another nicotine delivery method can benefit."
  • We are excited to have PUDO as a solution for millions of American adult consumers," says Conley.

Plant-based Nutritional Supplement Brand PlantFuel Taps College Athletes in Newly Launched Partnership Program

Wednesday, September 22, 2021 - 3:00pm

MISSISSAUGA, ON, Sept. 22, 2021 /PRNewswire/ -- PlantFuel Life Inc. (CSE: FUEL) (OTC: BLLXF) (FSE: BR1B) ("PlantFuel" or the "Company"), the scientifically focused plant-based wellness company, today announced members of its official College Athlete Partnerships Program. Following the NCAA's recent rule change, college athletes are now allowed to profit from their names, images and likeness (NIL), and PlantFuel is tapping into a diverse group of student athletes from a range of athletic talents. 

Key Points: 
  • MISSISSAUGA, ON, Sept. 22, 2021 /PRNewswire/ -- PlantFuel Life Inc. (CSE: FUEL) (OTC: BLLXF) (FSE: BR1B) ("PlantFuel" or the "Company"), the scientifically focused plant-based wellness company, today announced members of its official College Athlete Partnerships Program.
  • Following the NCAA's recent rule change, college athletes are now allowed to profit from their names, images and likeness (NIL), and PlantFuel is tapping into a diverse group of student athletes from a range of athletic talents.
  • "This is an entirely new frontier for brands to connect with college athletes," said PlantFuel Founder, Brad Pyatt.
  • Through PlantFuel's new program, athletes will promote the brand through social media activities, personal appearances, and content on the brand's website.

French Contemporary Artist Auguste Partners with Metaverse Blockchain Company Coinllectibles™️ to mint Fusion NFT™️

Wednesday, September 22, 2021 - 2:02pm

SINGAPORE, Sept. 22, 2021 /PRNewswire/ -- Coinllectibles, a metaverse blockchain company and a fullyowned subsidiary of Cosmos Group Holdings Inc. (OTC: COSG), is pleased to announce thecollaboration with French contemporary artist Auguste to create a unique, and one-of-a-kind"Auguste x Coinllectibles Crossover Fusion NFT".

Key Points: 
  • SINGAPORE, Sept. 22, 2021 /PRNewswire/ -- Coinllectibles, a metaverse blockchain company and a fullyowned subsidiary of Cosmos Group Holdings Inc. (OTC: COSG), is pleased to announce thecollaboration with French contemporary artist Auguste to create a unique, and one-of-a-kind"Auguste x Coinllectibles Crossover Fusion NFT".
  • Born in 1977, Alex Auguste is a French contemporary artist based in Bordeaux.
  • All of Auguste's works are signed and titledon the back with the name "Auguste" where it makes reference to the Roman Emperor.
  • Coinllectibles Fusion NFTs bridge the physical and virtual dimensions of the arts and collectiblesmarket, providing a pleasurable, transparent, and frictionless experience to customers from all walksof life.

Dominion Water Reserves Esker Development

Wednesday, September 22, 2021 - 1:30pm

MONTREAL, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Dominion Water Reserves Corp. (“DWR” or the “Company”) (CSE: DWR), is pleased to announce an investment of $250,000 toward the development of its esker water reserve. As part of its growth strategy and to accelerate its development, DWR will upgrade its installations to facilitate access to bulk transport markets. DWR’s 204 - acre water reserve in the Outaouais region has an authorized annual extraction volume of nearly 1 billion litres, making it the second esker with bottling permit in Quebec with 9.5% of the volume of Quebec’s collection authorizations.    Considering the high quality and available volume of this esker water, DWR is currently in discussion with potential partners, specializing in beverage manufacturing, to undertake its development and commercialization.

Key Points: 
  • MONTREAL, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Dominion Water Reserves Corp. (DWR or the Company) (CSE: DWR), is pleased to announce an investment of $250,000 toward the development of its esker water reserve.
  • Considering the high quality and available volume of this esker water, DWR is currently in discussion with potential partners, specializing in beverage manufacturing, to undertake its development and commercialization.
  • About Dominion Water Reserves Corp.
    DWRs operations are based in Quebec, with its primary business being a consolidator of the water industry by acquiring fresh spring water permits and developing operations across Quebec with plans to expand across North America.
  • DWRs mission is to acquire, manage and develop spring water assets building a critical mass in terms of capacity and strategically securing a leadership role in North Americas fresh spring water.